Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEVRO CORPNVRO · Entity 12422 | Chief Financial Officer | June 04, 2020 | June 08, 2020 |
| OOMA INCOOMA · Entity 2473 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEVRO CORP
Report date June 04, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,179 |
Reported balance
After 2020-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-04 · Tax withholding · Disposed 2,311 · Balance 59,179 F1: Includes 12,491 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 12,491 restricted stock units.
OOMA INC
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,824 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 9,743 · Balance 250,824 F1: 100% of the total number of restricted stock units shall vest on the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total number of restricted stock units shall vest on the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-28 · Other · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.87 · Expires 2035-03-18 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 16,829 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 1,784 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2018 Filed Jul 20, 2018 18:02 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,400 | $1.44 | $10,656.00 |
DisclosureSEC source: 0001140361-18-033064 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 00:39 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 10,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036543 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,277 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2019 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:10 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024283 · doc1.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,463 Underlying: Common Stock · 7,000 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:10 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 7,000 | $76.14 | $532,959.00 |
DisclosureSEC source: 0001140361-18-024283 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,192 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.85 to $76.64, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:10 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,000 | $18.00 | $126,000.00 |
DisclosureSEC source: 0001140361-18-024283 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:08 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-18-012018 · doc1.xml · derivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,463 Underlying: Common Stock · 7,000 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:08 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,460 | $80.87 | $118,065.82 |
DisclosureSEC source: 0001140361-18-012018 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,192 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $80.45 to $81.21, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:08 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 5,540 | $79.90 | $442,645.45 |
DisclosureSEC source: 0001140361-18-012018 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,652 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $79.39 to $80.36, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:08 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,000 | $18.00 | $126,000.00 |
DisclosureSEC source: 0001140361-18-012018 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,125 restricted stock units. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043114 · doc1.xml · derivative · entry 5 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,463 Underlying: Common Stock · 7,000 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $76.81 | $0.00 |
DisclosureSEC source: 0001140361-17-043114 · doc1.xml · derivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2027-11-13 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 14, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 7,000 | $75.11 | $525,739.90 |
DisclosureSEC source: 0001140361-17-043114 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,192 F3 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.38, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 18,125 RSUs. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,000 | $18.00 | $126,000.00 |
DisclosureSEC source: 0001140361-17-043114 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 18,125 RSUs. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043114 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,192 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on November 1 of each year, beginning November 1, 2018, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 18,125 RSUs. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 11:14 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001140361-17-041992 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,404 Underlying: Common Stock · 4,000 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 11:14 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 4,000 | $1.44 | $5,760.00 |
DisclosureSEC source: 0001140361-17-041992 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 5,125 restricted stock units. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 18:17 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 641 | $88.99 | $57,042.59 |
DisclosureSEC source: 0001140361-17-041043 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,192 F1 · balance_after: Includes 5,125 restricted stock units. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 204 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · derivative · entry 7 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,463 Underlying: Common Stock · 204 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,144 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · derivative · entry 6 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,286 Underlying: Common Stock · 6,144 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 652 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · derivative · entry 5 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,894 Underlying: Common Stock · 652 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 7,000 | $82.31 | $576,192.40 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · nonDerivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,833 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $81.94 to $82.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 204 | $18.00 | $3,672.00 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 6,144 | $3.60 | $22,118.40 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:49 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 652 | $3.60 | $2,347.20 |
DisclosureSEC source: 0001140361-17-032394 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| June 20, 2017 Filed Jun 23, 2017 00:14 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 12,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041498 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,365 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2018 annual stockholder meeting to be held on or about June 20, 2018, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| May 15, 2017 Filed May 16, 2017 16:54 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001140361-17-021014 · doc1.xml · derivative · entry 5 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,546 Underlying: Common Stock · 7,500 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 15, 2017 Filed May 16, 2017 16:54 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,306 | $76.40 | $99,781.93 |
DisclosureSEC source: 0001140361-17-021014 · doc1.xml · nonDerivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,833 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| May 15, 2017 Filed May 16, 2017 16:54 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 2,698 | $75.55 | $203,826.35 |
DisclosureSEC source: 0001140361-17-021014 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,139 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| May 15, 2017 Filed May 16, 2017 16:54 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 3,496 | $74.69 | $261,126.03 |
DisclosureSEC source: 0001140361-17-021014 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,837 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $73.96 to $74.94, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| May 15, 2017 Filed May 16, 2017 16:54 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,500 | $3.60 | $27,000.00 |
DisclosureSEC source: 0001140361-17-021014 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| May 09, 2017 Filed May 11, 2017 13:48 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001140361-17-019626 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,404 Underlying: Common Stock · 5,000 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 09, 2017 Filed May 11, 2017 13:48 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 5,000 | $1.44 | $7,200.00 |
DisclosureSEC source: 0001140361-17-019626 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:32 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 14,297 | $95.04 | $1,358,791.17 |
DisclosureSEC source: 0001140361-17-014934 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,833 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.83 to $95.27, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:32 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 9,166 | $94.32 | $864,569.20 |
DisclosureSEC source: 0001140361-17-014934 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,130 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $93.83 to $94.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:32 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 6,537 | $93.39 | $610,468.20 |
DisclosureSEC source: 0001140361-17-014934 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,296 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001140361-17-010555 · doc1.xml · derivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,046 Underlying: Common Stock · 7,500 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 300 | $95.77 | $28,729.53 |
DisclosureSEC source: 0001140361-17-010555 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,833 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $95.55 to $96.14, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 7,200 | $94.97 | $683,801.28 |
DisclosureSEC source: 0001140361-17-010555 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,133 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $94.53 to $95.45, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:51 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 7,500 | $3.60 | $27,000.00 |
DisclosureSEC source: 0001140361-17-010555 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,833 restricted stock units. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 18:24 UTC | NEVRO CORP NVRO · Entity 12422 | GrantStock Option (Right to Buy) · Derivative | 27,333 | $0.00 Strike: $87.62 | $0.00 |
DisclosureSEC source: 0001140361-16-087301 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,333 Underlying: Common Stock · 27,333 shares Expires 2026-11-15 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2016 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 18:24 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087301 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,833 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on November 1 of each year, beginning November 1, 2017, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 6,833 RSUs. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (right to buy) · Derivative | 4,185 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · derivative · entry 8 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,667 Underlying: Common Stock · 4,185 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (right to buy) · Derivative | 3,315 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · derivative · entry 7 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,546 Underlying: Common Stock · 3,315 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 2,906 | $87.55 | $254,416.23 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 6 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.27 to $87.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 3,734 | $86.75 | $323,941.68 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 5 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,906 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $86.24 to $87.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 660 | $85.70 | $56,562.86 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,640 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.17 to $86.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 200 | $84.17 | $16,833.00 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,300 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.14 to $84.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 4,185 | $18.00 | $75,330.00 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 18:26 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 3,315 | $3.60 | $11,934.00 |
DisclosureSEC source: 0001140361-16-087000 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.